Literature DB >> 28966886

Assessment of the Role of Different Imaging Modalities with Emphasis on Fdg Pet/Ct in the Management of Well Differentiated Thyroid Cancer (WDTC).

Tuba Karagulle Kendi A1, Shwetha Mudalegundi2, Jeffrey Switchenko3, Daniel Lee1, Raghuveer Halkar1, Amy Y Chen4.   

Abstract

BACKGROUND: Positron emission tomography/computed tomography is suggested to have a role in detection of iodine negative recurrence in well differentiated thyroid cancer. The aim of this study is to identify role of different imaging modalities in the management of well differentiated thyroid cancer.
METHODS: We reviewed 900 well differentiated thyroid cancer patients after post-thyroidectomy who underwent recombinant human thyroid stimulating hormone stimulated Sodium Iodide I 131 imaging. Out of 900 patients, 74 had positron emission tomography/computed tomography. Multivariate analysis was performed by controlling positron emission tomography/computed tomography, Sodium Iodide I 131 scan, neck ultrasonography, age, sex, primary tumor size, stage, histology, thyroglobulin. Patients were grouped according to results of Sodium Iodide I 131 scan and positron emission tomography/computed tomography.
RESULTS: Positron emission tomography/computed tomography was positive in 23 of 74 patients. The sensitivity for positron emission tomography was 11/11(100%), the specificity was 51/63 (81.0%), the positive predictive value was 11/23 (47.8%), and the negative predictive value was 51/51 (100%). The sensitivity for the neck ultrasonography was 4/8 (50%), the specificity was 53/60 (88.3%), positive predictive value was 4/11 (36.4%), and negative predictive value was 53/57 (93.0%). 50% of patients who had Sodium Iodide I 131 negative scan and positive positron emission tomography/computed tomography had a change in management. Thirty-six percent with positive neck ultrasonography had a change in management. Out of 11 recurrences, 6 had distant metastatic disease, and 5/11 had regional nodal disease. Neck ultrasonography showed nodal metastasis in 4/5 (80%).
CONCLUSION: Positron emission tomography/computed tomography altered management in the presence of a high thyroglobulin level and a negative Sodium Iodide I 131 scan. Neck ultrasonography should be the first line of imaging with rising thyroglobulin levels. Positron emission tomography/computed tomography should be considered for cases with high thyroglobulin levels and normal neck ultrasonography to look for distant metastatic disease.

Entities:  

Keywords:  Neck ultrasound; Positron emission tomography; Thyroglobulin; Well differentiated thyroid cancer

Year:  2016        PMID: 28966886      PMCID: PMC5616213          DOI: 10.4172/2167-7948.1000202

Source DB:  PubMed          Journal:  J Thyroid Disord Ther        ISSN: 2167-7948


  24 in total

1.  Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?

Authors:  Peter Bannas; Thorsten Derlin; Michael Groth; Ivayla Apostolova; Gerhard Adam; Janos Mester; Susanne Klutmann
Journal:  Ann Nucl Med       Date:  2011-10-19       Impact factor: 2.668

2.  Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas.

Authors:  Agnès Rouxel; Gilles Hejblum; Marie-Odile Bernier; Pierre-Yves Boëlle; Fabrice Ménégaux; George Mansour; Catherine Hoang; André Aurengo; Laurence Leenhardt
Journal:  J Clin Endocrinol Metab       Date:  2004-11       Impact factor: 5.958

3.  Clinical value of integrated [18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the preoperative assessment of papillary thyroid carcinoma: comparison with sonography.

Authors:  Woo Hee Choi; Yong-An Chung; Eun Ji Han; Hyung Sun Sohn; Sang Hoon Lee
Journal:  J Ultrasound Med       Date:  2011-09       Impact factor: 2.153

Review 4.  Detection of residual and recurrent thyroid cancer by radionuclide imaging.

Authors:  H R Maxon
Journal:  Thyroid       Date:  1999-05       Impact factor: 6.568

5.  Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer.

Authors:  Jaime L Wiebel; Nazanene H Esfandiari; Maria Papaleontiou; Francis P Worden; Megan R Haymart
Journal:  Thyroid       Date:  2015-08-03       Impact factor: 6.568

6.  Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan.

Authors:  Won Gu Kim; Jin-Sook Ryu; Eui Young Kim; Jeong Hyun Lee; Jung Hwan Baek; Jong Ho Yoon; Suck Joon Hong; Eun Sook Kim; Tae Yong Kim; Won Bae Kim; Young Kee Shong
Journal:  J Clin Endocrinol Metab       Date:  2010-01-15       Impact factor: 5.958

7.  Comparison of 18F-fluorodeoxyglucose uptake with the expressions of glucose transporter type 1 and Na+/I- symporter in patients with untreated papillary thyroid carcinoma.

Authors:  Seung Hwan Moon; Young Lyun Oh; Joon Young Choi; Chung-Hwan Baek; Young-Ik Son; Han-Sin Jeong; Yearn Seong Choe; Kyung-Han Lee; Byung-Tae Kim
Journal:  Endocr Res       Date:  2012-08-13       Impact factor: 1.720

8.  Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays.

Authors:  M Schlumberger; O Arcangioli; J D Piekarski; M Tubiana; C Parmentier
Journal:  J Nucl Med       Date:  1988-11       Impact factor: 10.057

9.  The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer.

Authors:  M W Ashcraft; A J Van Herle
Journal:  Am J Med       Date:  1981-11       Impact factor: 4.965

10.  F18-FDG-PET for recurrent differentiated thyroid cancer: a systematic meta-analysis.

Authors:  Torjan Haslerud; Katrin Brauckhoff; Lars Reisæter; Regina Küfner Lein; Achim Heinecke; Jan Erik Varhaug; Martin Biermann
Journal:  Acta Radiol       Date:  2015-07-09       Impact factor: 1.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.